Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys

Annals of Neurology

Volumn 42, Issue 2, 1997, Pages 208-214

  Miyoshi, Yasuyuki ^a   Zhang, Zhiming ^a   Ovadia, Aliza ^a   Lapchak, Paul A ^b   Collins, Frank ^b   Hilt, Dana ^b   Lebel, Carl ^b   Kryscio, Richard ^a   Gash, Don M ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSKINESIA; DYSTONIA; FEMALE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NEUROMODULATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RHESUS MONKEY; STEREOTYPY; TOXICITY TESTING; VOMITING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; CARBIDOPA; CEREBRAL VENTRICLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INJECTIONS, INTRAVENTRICULAR; LEVODOPA; MACACA MULATTA; MOTOR ACTIVITY; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; STEREOTYPED BEHAVIOR;

EID: 0030838127     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420212     Document Type: Article

References (41)

1. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;45:19-34
2. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1986;45:1-18
3. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982;139:494-497
4. Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260
5. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancer 1977; 1:345-349
6. Pederzoli M, Girotti F, Scigliano G, et al. L-Dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology 1983;33:1518-1522
7. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993;43(suppl 6):47-52
8. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals; possible participation of levodopa. Adv Neurol 1993;60:242-250
9. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur Neurol 1994;34(suppl 3):20-28
10. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7: 23-31
11. Mena MA, Pardo B, Paino CL, et al. Levodopa toxicity in foetal rat midbrain neurons in culture: modulation by ascorbic acid. Neuropharmacol Neurotoxicol 1993;4:438-440
12. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced de-generation in the adult brain. Nature 1995;373:339-341
13. Gash DM, Zhang Z, Cass WA, et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 1995;363:345-358
14. Hoffer BJ, Hoffman A, Bowenkamp K, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994; 182:107-111
15. Hudson J, Granholm A-C, Gerhardt GA, et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 1995;36:425-432
16. Lin L-FH, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132
17. Lapchak PA. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS. Rev Neurosci 1996;7:165-176
18. Schaar DG, Sieber B-A, Dreyfus CF, et al. Regional and cell-specific expression of GDNF in rat brain. Exp Neurol 1993; 124:368-371
19. Springer JE, Mu X, Bergmann LW, et al. Expression of GDNF mRNA in rat and human nervous tissue. Exp Neurol 1994; 127:167-170
20. Stromberg I, Bjorklund L, Johansson M, et al. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 1993;124:401-412
21. Tomac A, Lindqvist E, Lin L-FH, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373:335-339
22. Bowenkamp KE, Hoffman AF, Gerhardt GA, et al. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 1995;355: 479-489
23. Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995;672: 104-111
24. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380: 252-255
25. Ovadia A, Zhang Z, Gash DM. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging 1995;16:931-937
26. Smith RD, Zhang Z, Kurlan R, et al. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 1993;52:7-16
27. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880
28. Tetrud JW, Langston JW. MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurol Scand 1989;126: 35-40
29. Mouradian MM, Chase TN. Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385
30. Boyce S, Rupniak NMJ, Steventon MJ, et al. Differential effects of D1 or D2 agonist in MPTP-treated primates: functional implication for Parkinson's disease. Neurology 1990;40: 927-933
31. Mouradian MM, Heuser IJE, Baronti F, et al. Pathogenesis of dyskinesia in Parkinson's disease. Ann Neurol 1989;25:523-526
32. Blanchet P, Bedard PJ, Britton DR, et al. Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267: 275-279
33. Crossman AR. A hypothesis on the pathological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108
34. Calon F, Goulet M, Blanchet PJ, et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res 1995;680:43-52
35. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578
36. Double KL, Crocker AD. Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc Natl Acad Sci USA 1995;92:1669-1673
37. Hornykiewicz O. Biochemical abnormalities in some extrastriatal neuronal systems in Parkinson's disease. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's disease - current progress, problems and management. Amsterdam: Elsevier, 1980: 109-119
38. Kuno S. Dilemma in the treatment of Parkinson's disease with L-dopa. Eur Neurol 1994;34(suppl 3): 17-19
39. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990;13:244-254
40. + evoked overflow of dopamine in rat striatum. Soc Neurosci Abstr 1995;21:541 (Abstract)
41. 3H]spiperone binding. Brain Res 1986;379:294-299